Table 1.
Demographic and clinical characteristics of the matched populations at baseline that were unvaccinated or received a single dose of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines.
| Unvaccinated (N = 127,216) | Oxford-AstraZeneca (N = 63,608) | Pfizer (N = 63,608) | |
|---|---|---|---|
| Age in years [median (IQR)] | 53 (41–61) | 53 (41–61) | 53 (41–61) |
| Male [n(%)] | 58,796 (46.2%) | 29,398 (46.2%) | 29,398 (46.2%) |
| At risk age 16–64 [n(%)] | 12,938 (10.2%) | 6469 (10.2%) | 6469 (10.2%) |
| Care home resident [n(%)] | 6 (0.005%) | 3 (0.005%) | 3 (0.005%) |
| Clinically extremely vulnerable [n(%)] | 2114 (1.7%) | 1057 (1.7%) | 1057 (1.7%) |
| Ethnicity [n(%)] | |||
| White | 58,644 (46.1%) | 29,322 (46.1%) | 29,322 (46.1%) |
| South Asian | 28,252 (22.2%) | 14,126 (22.2%) | 14,126 (22.2%) |
| Black | 8464 (6.7%) | 4232 (6.7%) | 4232 (6.7%) |
| Other Asian | 11,692 (9.2%) | 5846 (9.2%) | 5846 (9.2%) |
| Mixed/other | 8278 (6.5%) | 4139 (6.5%) | 4139 (6.5%) |
| Not reported/recorded | 11,886 (9.3%) | 5943 (9.3%) | 5943 (9.3%) |
| Comorbidities [n(%)] | |||
| 0 | 74,912 (58.9%) | 37,456 (58.9%) | 37,456 (58.9%) |
| 1 | 30,228 (23.8%) | 15,114 (23.8%) | 15,114 (23.8%) |
| 2 | 14,680 (11.5%) | 7340 (11.5%) | 7340 (11.5%) |
| 3 | 5076 (4.0%) | 2538 (4.0%) | 2538 (4.0%) |
| 4+ | 2320 (1.8%) | 1160 (1.8%) | 1160 (1.8%) |
| IMD decile [n(%)] | |||
| 1 | 1372 (1.1%) | 686 (1.1%) | 686 (1.1%) |
| 2 | 12,308 (9.7%) | 6154 (9.7%) | 6154 (9.7%) |
| 3 | 19,244 (15.1%) | 9622 (15.1%) | 9622 (15.1%) |
| 4 | 22,548 (17.7%) | 11,274 (17.7%) | 11,274 (17.7%) |
| 5 | 20,804 (16.4%) | 10,402 (16.4%) | 10,402 (16.4%) |
| 6 | 17,396 (13.7%) | 8698 (13.7%) | 8698 (13.7%) |
| 7 | 11,828 (9.3%) | 5914 (9.3%) | 5914 (9.3%) |
| 8 | 11,896 (9.4%) | 5948 (9.4%) | 5948 (9.4%) |
| 9 | 7206 (5.7%) | 3603 (5.7%) | 3603 (5.7%) |
| 10 | 2614 (2.1%) | 1307 (2.1%) | 1307 (2.1%) |
| Number of tests before week of matching [n(%)] | |||
| 0 | 124,566 (97.9%) | 62,283 (97.9%) | 62,283 (97.9%) |
| 1 | 2394 (1.9%) | 1197 (1.9%) | 1197 (1.9%) |
| 2+ | 256 (0.2%) | 128 (0.2%) | 128 (0.2%) |
| Comorbidities [n(%)] | |||
| Anxiety | 13,631 (10.7%) | 4842 (7.6%) | 4505 (7.1%) |
| Asthma | 122,626 (3.6%) | 3947 (6.2%) | 4245 (6.7%) |
| Atrial fibrillation | 796 (0.6%) | 459 (0.7%) | 584 (0.9%) |
| Cancer | 1821 (1.4%) | 1184 (1.9%) | 1336 (2.1%) |
| CKD | 782 (0.6%) | 419 (0.7%) | 517 (0.8%) |
| COPD | 913 (0.7%) | 507 (0.8%) | 564 (0.9%) |
| Dementia | 195 (0.2%) | 124 (0.2%) | 87 (0.1%) |
| Depression | 13,441 (10.6%) | 4882 (7.7%) | 4561 (7.2%) |
| Diabetes | 8153 (6.4%) | 6355 (10.0%) | 6807 (10.7%) |
| Heart failure | 340 (0.3%) | 187 (0.3%) | 198 (0.3%) |
| Hypertension | 19,014 (15.0%) | 9258 (14.6%) | 9046 (14.2%) |
| Hypothyroidism | 6505 (5.1%) | 2748 (4.3%) | 2557 (4.0%) |
| IHD | 2085 (1.6%) | 1321 (2.1%) | 1337 (2.1%) |
| Learning disability | 241 (0.2%) | 225 (0.4%) | 162 (0.3%) |
| Mental health | 2282 (1.8%) | 642 (1.0%) | 559 (0.9%) |
| Obesity | 8554 (6.7%) | 4559 (7.2%) | 4588 (7.2%) |
| PAD | 273 (0.2%) | 182 (0.3%) | 134 (0.2%) |
| Palliative care | 144 (0.1%) | 86 (0.1%) | 50 (0.1%) |
| Parkinson's | 102 (0.1%) | 54 (0.1%) | 54 (0.1%) |
| Rheumatoid arthritis | 568 (0.4%) | 312 (0.5%) | 354 (0.6%) |
| Stroke or TIA | 1056 (0.8%) | 551 (0.9%) | 533 (0.8%) |
CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; PAD, peripheral arterial disease; IHD, Ischaemic heart disease; IQR, Interquartile range; TIA, Transient ischaemic attack.